{"id":161181,"date":"2026-09-07T13:17:23","date_gmt":"2026-09-07T13:17:23","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/161181\/"},"modified":"2026-09-07T13:17:23","modified_gmt":"2026-09-07T13:17:23","slug":"novo-nordisk-semaglutide-trial-shows-40-4-of-children-moved-below-obesity-bmi-threshold","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/161181\/","title":{"rendered":"Novo Nordisk Semaglutide Trial Shows 40.4% of Children Moved Below Obesity BMI Threshold"},"content":{"rendered":"<p class=\"mb-4 text-lg md:leading-8 break-words\">Novo Nordisk (NYSE:NVO) said on Monday that 40.4% of children with obesity who received once-weekly semaglutide in its phase 3 STEP Young trial achieved a body mass index below the obesity threshold after 68 weeks.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">The study enrolled 165 children aged 6 to under 12 with obesity. Participants received either semaglutide or placebo alongside lifestyle interventions that included a reduced-calorie diet and increased physical activity.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">None of the children in the placebo group achieved a BMI below the obesity threshold during the same period, according to the company.<\/p>\n<p>STEP Young trial meets primary endpoint<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">Novo Nordisk said the trial met its primary endpoint by demonstrating a greater reduction in BMI among children receiving semaglutide compared with placebo.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">At the beginning of the study, more than 85% of participants were classified as having class II or class III severe obesity, corresponding to a BMI of at least 35 or 40, respectively, in adults.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">Children received a maximum semaglutide dose of either 1.7 mg or 2.4 mg depending on their baseline weight. The treatment was administered by subcutaneous injection once a week.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">&#8220;Most of the children in the STEP Young trial were classified as having severe (class II or III) obesity at baseline, yet treatment with semaglutide resulted in a BMI percentile category below the obesity threshold in approximately 40% of the children within about a year of treatment,&#8221; said Ania M. Jastreboff, Professor of Medicine and Pediatrics at Yale and Director of the Yale Obesity Research Center.<\/p>\n<p>Novo Nordisk reports no new safety concerns<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">Novo Nordisk said the safety and tolerability profile observed in STEP Young was consistent with previous paediatric and adult studies involving semaglutide and liraglutide.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">The company reported no new safety concerns and said no safety issues related to growth or pubertal development were identified.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">An estimated 177 million children aged 5 to 19 were living with obesity in 2025, with projections indicating the figure could reach 228 million by 2040.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">Novo Nordisk plans to present detailed results from STEP Young at The Obesity Society&#8217;s ObesityWeek 2026 annual meeting, scheduled for November 14-17 in Washington, D.C.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">Novo Nordisk stock price<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk (NYSE:NVO) said on Monday that 40.4% of children with obesity who received once-weekly semaglutide in its&hellip;\n","protected":false},"author":2,"featured_media":161182,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[15247,272,75596,27784],"class_list":["post-161181","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-bmi","tag-novo-nordisk","tag-yale","tag-young"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117229954491676497","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/161181","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=161181"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/161181\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/161182"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=161181"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=161181"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=161181"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}